Home Newsfeeds Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

byBenzinga Newsdesk

September 13, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

Genpact Narrows Guidance Sees FY22 Revenue $4.32B-$4.37B Vs $4.27B Est

By Benzinga Newsdesk

August 4, 5:29 PM

Full Year 2022 Outlook Genpact now expects: Total revenue in the range of $4.32 billion to $4.37 billion, up 7.5% to 9.0%, or 9.5% to 11.0% on a constant

Dow Falls Over 100 Points; Phillips 66 Posts Upbeat Results

By Lisa Levin

August 2, 9:50 AM

U.S. stocks were lower this morning, with the Dow Jones falling over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.40% to 35,489.70 while the NASDAQ fell 1.40% to 14,084.03. The S&P 500, also fell, dropping, 0.85% to 4,537.84.

ADMP